Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
Top Cited Papers
- 29 August 2019
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 381 (9), 816-826
- https://doi.org/10.1056/nejmoa1904340
Abstract
An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz–based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings.Keywords
Funding Information
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales (ANRS12314)
- UNITAID (NAMSAL Trial)
This publication has 25 references indexed in Scilit:
- Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trialThe Lancet, 2014
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 InfectionThe New England Journal of Medicine, 2013
- Adverse events associated with nevirapine and efavirenz-based first-line antiretroviral therapyAIDS, 2013
- Design of HIV noninferiority trialsAIDS, 2013
- Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort studyThe Lancet Infectious Diseases, 2012
- A Meta-analysis to Assess the FDA DAVP’s TLOVR Algorithm in HIV SubmissionsDrug Information Journal, 2011
- Designing and interpreting HIV noninferiority trials in naive and experienced patientsAIDS, 2008
- The short‐form version of the Depression Anxiety Stress Scales (DASS‐21): Construct validity and normative data in a large non‐clinical sampleBritish Journal of Clinical Psychology, 2005
- A 12-Item Short-Form Health SurveyMedical Care, 1996